SG11202106491VA - Modulation of rep protein activity in closed-ended dna (cedna) production - Google Patents

Modulation of rep protein activity in closed-ended dna (cedna) production

Info

Publication number
SG11202106491VA
SG11202106491VA SG11202106491VA SG11202106491VA SG11202106491VA SG 11202106491V A SG11202106491V A SG 11202106491VA SG 11202106491V A SG11202106491V A SG 11202106491VA SG 11202106491V A SG11202106491V A SG 11202106491VA SG 11202106491V A SG11202106491V A SG 11202106491VA
Authority
SG
Singapore
Prior art keywords
cedna
modulation
closed
production
protein activity
Prior art date
Application number
SG11202106491VA
Other languages
English (en)
Inventor
Robert Kotin
Anna Ucher
Ara Malakian
Original Assignee
Generation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generation Bio Co filed Critical Generation Bio Co
Publication of SG11202106491VA publication Critical patent/SG11202106491VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/002—Vectors comprising a special origin of replication system inducible or controllable
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202106491VA 2019-02-15 2020-02-14 Modulation of rep protein activity in closed-ended dna (cedna) production SG11202106491VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962806076P 2019-02-15 2019-02-15
PCT/US2020/018332 WO2020168222A1 (en) 2019-02-15 2020-02-14 Modulation of rep protein activity in closed-ended dna (cedna) production

Publications (1)

Publication Number Publication Date
SG11202106491VA true SG11202106491VA (en) 2021-07-29

Family

ID=72045641

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106491VA SG11202106491VA (en) 2019-02-15 2020-02-14 Modulation of rep protein activity in closed-ended dna (cedna) production

Country Status (11)

Country Link
US (1) US20220127625A1 (cg-RX-API-DMAC7.html)
EP (1) EP3924491A4 (cg-RX-API-DMAC7.html)
JP (2) JP7644014B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210127935A (cg-RX-API-DMAC7.html)
CN (1) CN113454232B (cg-RX-API-DMAC7.html)
AU (1) AU2020221312A1 (cg-RX-API-DMAC7.html)
CA (1) CA3129321A1 (cg-RX-API-DMAC7.html)
IL (1) IL285415A (cg-RX-API-DMAC7.html)
MA (1) MA54958A (cg-RX-API-DMAC7.html)
SG (1) SG11202106491VA (cg-RX-API-DMAC7.html)
WO (1) WO2020168222A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020001593A (es) 2017-08-09 2020-07-13 Bioverativ Therapeutics Inc Moleculas de acido nucleico y usos de las mismas.
JP7602454B2 (ja) 2018-08-09 2024-12-18 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
PE20220233A1 (es) * 2019-06-10 2022-02-07 Homology Medicines Inc Composiciones de virus adenoasociados para la transferencia del gen de arsa y metodos de uso de las mismas
MX2023001109A (es) 2020-07-27 2023-04-24 Anjarium Biosciences Ag Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas.
MX2023003019A (es) * 2020-09-16 2023-05-08 Generation Bio Co Vectores de adn de extremo cerrado y usos de estos para expresar fenilalanina hidroxilasa (pah).
US20240091382A1 (en) * 2020-12-23 2024-03-21 Vivet Therapeutics Minimal bile acid inducible promoters for gene therapy
TW202302858A (zh) * 2021-03-16 2023-01-16 威斯康辛校友研究基金會 治療糖尿病之胰島素基因療法
WO2023028440A2 (en) * 2021-08-23 2023-03-02 Bioverativ Therapeutics Inc. Baculovirus expression system
CN114703203B (zh) * 2022-02-11 2024-08-06 上海渤因生物科技有限公司 杆状病毒载体及其用途
KR102737146B1 (ko) * 2023-07-10 2024-12-09 대한민국 신규 발현 벡터 및 이의 용도
CN122341729A (zh) * 2023-11-30 2026-07-03 赛诺菲 末端封闭的dna分子的纯化
US12509711B1 (en) * 2024-08-09 2025-12-30 Martin Williams System and process for in vivo manufacturing nanostructure-ended double-stranded covalently-closed linear DNA, the resulting molecules and their uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2596292C (en) * 1997-03-21 2012-05-22 Enzo Therapeutics, Inc. Vectors and viral vectors, and packaging cell lines for propagating same
CN1183257C (zh) * 1999-10-29 2005-01-05 宝生物工程株式会社 基因转移的方法
WO2007148971A2 (en) * 2006-06-21 2007-12-27 Amsterdam Molecular Therapeutics B.V. Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells
EP2545165B1 (en) * 2010-03-11 2020-07-29 uniQure IP B.V. Mutated rep encoding sequences for use in aav production
EP2500434A1 (en) * 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
WO2015137802A1 (en) * 2014-03-10 2015-09-17 Uniqure Ip B.V. Further improved aav vectors produced in insect cells
IL261524B2 (en) * 2016-03-03 2023-10-01 Univ Massachusetts End-capped linear double-stranded DNA for non-viral gene transfer
MX2020001593A (es) * 2017-08-09 2020-07-13 Bioverativ Therapeutics Inc Moleculas de acido nucleico y usos de las mismas.

Also Published As

Publication number Publication date
MA54958A (fr) 2021-12-22
EP3924491A4 (en) 2022-12-14
CA3129321A1 (en) 2020-08-20
AU2020221312A1 (en) 2021-10-07
WO2020168222A1 (en) 2020-08-20
US20220127625A1 (en) 2022-04-28
CN113454232A (zh) 2021-09-28
CN113454232B (zh) 2024-10-29
JP2024083567A (ja) 2024-06-21
KR20210127935A (ko) 2021-10-25
EP3924491A1 (en) 2021-12-22
IL285415A (en) 2021-09-30
JP2022520803A (ja) 2022-04-01
JP7644014B2 (ja) 2025-03-11

Similar Documents

Publication Publication Date Title
IL285415A (en) Modulation of rep protein activity in closed-end DNA production
IL282925A (en) A modified closed-end DNA (cedna) that contains symmetrically altered inverted terminal repeats
MX2021015182A (es) Casetes optimizados de expresion del gen humano del factor viii de coagulacion y su uso.
DK3740222T5 (da) Modificeret RAAV-capsidprotein til genterapi
IL275244B (en) Use of programmable DNA-binding proteins to enhance targeted genome modification
IL276658A (en) Controlled expression of transgenes using closed-end DNA vectors
PH12019500122A1 (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
MX2023001119A (es) Variantes de enzimas y polinucleotidos que las codifican.
SG11202103425YA (en) Engineered nucleic acid constructs encoding aav production proteins
PH12018501055A1 (en) Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders
HK1254803A1 (zh) 新型pd -1的免疫调节剂
AU2018275549A1 (en) Optimized human clotting factor IX gene expression cassettes and their use
JOP20220079A1 (ar) بروتين ربط متعددة الخصوصية لمعالجة السرطان
CY1117423T1 (el) Παραγοντες που επηρεαζουν αποπτωση για τη θεραπεια καρκινου και ανοσων και αυτοανοσων ασθενειων
MX363017B (es) Métodos y productos para la expresión de proteínas en células.
EP3997205A4 (en) Rna sequencing methods
MX2020001282A (es) Polipeptidos que tienen actividad trehalasa y uso de los mismos en proceso de produccion de productos de fermentacion.
WO2015158808A3 (en) Recombinant host cell engineered to overexpress helper proteins
EP4073231A4 (en) RECOMBINANT CDKL5 PROTEINS, GENE THERAPY AND MANUFACTURING METHODS
MX2019013124A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
IL286031A (en) Closed-end DNA compounds and immune modulators
BR112017028035A2 (pt) aminopeptidases para hidrolisados de proteína
HK40061295A (en) Modulation of rep protein activity in closed-ended dna (cedna) production
SG11202112867VA (en) Novel artificial protein catalyst
HK40061131A (en) Modified closed-ended dna (cedna) comprising symmetrical modified inverted terminal repeats